Prophylactic Use of Intraumbilical Vein Oxytocin Injection in The Management of Third Stage of Labor

Ain Shams University

Status and phase: Unknown; Phase 1

Conditions: Postpartum Hemorrhage

Treatments: Drug: saline; Drug: oxytocin

Study type: Interventional

Funder types: Other

Identifiers

NCT02680938

gyn-057

Details and patient eligibility

About

The third stage is the interval between delivery of the infant and delivery of the placenta. This stage averages 10 minutes and is considered prolonged if it lasts longer than 30 minutes, placental separation occurs as a result of continued uterine contractions, continued contractions control blood loss by compression of spiral arteries and also result in migration of the placenta into the lower uterine segment and then through the cervix.

The intra-umbilical vein injection of 10 IU of oxytocin is recommended as a first line of treatment for retained placenta. Despite this recommendation, the method has yet to make its way into routine practice, probably because of the lack of a large substantive randomized controlled trial, and lingering doubts over which uterotonic to use and at what dosage.

The purpose of this study is to evaluate the effect of intraumbilical vein injection of oxytocin on reducing the duration of the third stage of labor and the need for manual delivery of placenta, ,in addition to reduce blood loss during third and fourth stage of labor and decrease incidence of rtained placenta in comparison with inraumblical injection of normal saline.

This is a prospective randomized control trial conducted at Ain Shams University Maternity Hospital. This study included 240 term pregnant women in labor admitted to the labor ward, They were divided into Two groups :

Group (A):

The experimental group, 10 units of oxytocin will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.

Group (B):

The control group, 1 mL normal saline will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.

Full description

This study included 240 term pregnant women in labor admitted to the labor ward, They were divided into Two groups :

Group (A):

The experimental group, 10 units of oxytocin will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.

Group (B):

The control group, 1 mL normal saline will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.

complete blood count of both groups before and 12 h after delivery.

• The third stage of labor will be actively managed in the two groups by infusion of 20 IU oxytocin in 1 L Ringer's lactate solution at a rate of 100 mL/min, immediately after delivery of the fetus ( Nankali et al., 2013)..

• In the control group ( B ) , 1 mL normal saline will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.

• In the experimental group ( A ) , instead of normal saline, 10 IU (1mL) oxytocin will be injected at the same site. We will wait 30 min for the symptoms of placenta delivery (i.e., the uterus became firmer and more globular and was displaced upward, a gush of blood occurred, and the umbilical cord was elongated).

• Spontaneous delivery of the placenta will be achieved by touching the fundus and applying pressure on the symphysis pubis by a finger and slight traction of the umbilical cord.

• For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.

• The two groups will be compared in the following terms:

  1. The duration of the third stage of labor by stopwatch.
  2. Hemoglobin (Hb) difference before and 12 h after delivery.
  3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery.
  4. Estimate blood loss by Allowable Blood Loss (ABL) (Miller 2000)

Enrollment: 1 estimated patient

Sex: Female

Ages: 14 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. 36 to 42 weeks gestational age.
2. Single alive fetus with cephalic presentation.
3. Parity 1 to 3.
4. Normal vaginal delivery.

Exclusion criteria

1. Placenta Previa.
2. Placental Abruption .
3. Prolonged Labor ( > 20 h )
4. History of Postpartum Hemorrhage or Antepartum Hemorrhage.
5. History of Cesarean delivery or any uterine scar .
6. Polyhydramnios .
7. Known uterine anomalies.
8. Coagulation disorders.
9. Abnormal placental adhesion.
10. Forceps or Vacuum delivery.
11. Chorioamninitis.
12. Multiple Gestations.
13. Accelerated Labor (< 3 h ).
14. Painless Labor with Epidural Anaethesia

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

1 participants in 2 patient groups, including a placebo group

oxytocin group

Active Comparator group

Description:

10 units of oxytocin will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.

Treatment:

Drug: oxytocin

control group

Placebo Comparator group

Description:

1 mL normal saline will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.

Treatment:

Drug: saline